File this one under “Hope.” On June 4th, the New York Times posted an article about studies that are being conducted on the drug, Avastin (which is a widely known ‘cancer drug’) on how it would effect the progression of ovarian cancer.
The Avastin studies were discussed at the annual meeting of the American Society of Clinical Oncology, finding that the drug is effective in delaying the spreading of ovarian cancer – yet there is still speculation about how significant these results really are.
The piece in the NYT also discusses trials run on the drug exemestane, which is classified as an aromatase inhibitors (which are commonly used to prevent “a recurrence of cancer in women with early-stage breast cancer after their tumors are removed by surgery”); the tests are looking to see how effective exemestane iz in preventing breast cancer in post-menopausal women.
Learn about MSP posts as they happen by following us on Twitter@mysexprofessor or make friends with us on Facebook. You can also follow Madeline Haller, the author of this post, @voiceMLINE.